The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Sawai Fudged Quality Tests of Gastritis Drug for 8 Years, Awaiting Penalty Decision
October 24, 2023
-
BUSINESS Daiichi Sankyo, Merck in Global ADC Deal Worth Up to US$22 Billion
October 23, 2023
-
REGULATORY Chuikyo Wants Sakigake Premium Review as a Package with Regulatory Reform
October 23, 2023
-
BUSINESS Medicon, Mucodyne among Drugs Subject to MHLW’s Ramp-Up Request
October 20, 2023
-
BUSINESS Oncology, Cell & Gene Therapies Key Priorities for Bayer Co.Labs: Global Head
October 20, 2023
-
REGULATORY China Formally Arrests Astellas Employee, Japan Urges Immediate Release
October 20, 2023
-
REGULATORY Japan to Buy 10 Million More Doses of Pfizer/Moderna COVID Jabs
October 19, 2023
-
REGULATORY Health Minister Requests 8 Makers to Bolster Supplies of Antitussive, Expectorant Agents
October 19, 2023
-
REGULATORY Chuikyo at Odds over Handling of Startups in PMP, Timing of Deferred Price Cuts
October 19, 2023
-
BUSINESS BMS Looks to Double Japan Biz in Next 10 Years with Partnership as a Pillar
October 19, 2023
-
REGULATORY Average Price Gap for 2024 Revision Looks to Be Lower than 7.0%: Wholesalers
October 18, 2023
-
BUSINESS IBM Leads Development of Integrated Drug Supply Database for Wholesaler Reps, Pharmacists
October 18, 2023
-
REGULATORY AMED Group to Draft Master Protocols Guidelines by March-End, Frets Further Drug Lag/Loss
October 17, 2023
-
REGULATORY Health Minister Laments Drug Lag/Loss, Stresses Need for Govt-Driven Innovation Ecosystem
October 16, 2023
-
REGULATORY MHLW Regulatory Panel OKs New Procedures for Post-Approval Manufacturing Changes
October 16, 2023
-
BUSINESS Shonan iPark Looks to Woo Korean Firms by Partnering with Govt: Chief
October 13, 2023
-
ORGANIZATION Chuikyo Rep Interview 2-3 - With 80% Generic Share, Now Is the Time to Revisit LLP Copay, Says Payer Rep
October 13, 2023
-
REGULATORY MHLW Panel Proposes Assessing Generic Makers’ Efforts toward Stable Supplies, Reflecting Results in Pricing
October 12, 2023
-
REGULATORY Vyvgart, Dysval Braced for Price Cuts after CEA, No Change for Ondexxya
October 12, 2023
-
ACADEMIA G1 Product Info Could Disappear after Withdrawal, PMDA Website Should Retain Posting: Pharmacist
October 11, 2023
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…